The results indicate that GLP-1 receptor agonists may serve as an important choice in our quarry, namely obesity in patients with HFpEF, especially for those in which type 2 diabetes mellitus co-exists [59]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.